MedMira Inc. Announces to Launch VYRA™ CoV2Flu Rapid Antigen Rapid Test
Summary – Launch of VYRA™ CoV2Flu Rapid Antigen Rapid Test (VYRA™ CoV2Flu). Based on MedMira’s proprietary technology, this 3-in-1 test is developed…
Summary – Launch of VYRA™ CoV2Flu Rapid Antigen Rapid Test (VYRA™ CoV2Flu). Based on MedMira’s proprietary technology, this 3-in-1 test is developed…
Summary – New IND Expands Liver Disease Pipeline for CRV431 IND Clearance Allows CRV431 to Move Directly into Phase 2 for Hepatocellular…
Synopsis : Company announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase…
HIGHLIGHTS $50 million term sheet executed with Sprott Private Resource Streaming and Royalty Corp (“SRSR”) outlining a proposed financing package to fund…
Summary – Finning International Inc. (TSX: FTT) (“Finning”) today announced that, in connection with its previously announced normal course issuer bid (“NCIB”)…
Synopsis : Received notification to Review of the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for the treatment of breakthrough…
Synopsis: CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as…
Synopsis: VYVGART is the first-and-only FDA-approved neonatal Fc receptor blocker 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART…
Synopsis : BCI Pharma and Mithra will start a collaboration to deliver new therapy for women! Mithra acquires the right relating to…
Synopsis: Aptinyx Inc., a clinical-stage biopharmaceutical company, announced the initiation of a phase 2b study evaluating 50 mg QD of NYX-783 in…